Korean J Urol Oncol.  2020 Aug;18(2):124-139. 10.22465/kjuo.2020.18.2.124.

Management of Patients With Advanced Prostate Cancer: Establishment ofTreatment Guidelines Through Prostate Cancer Summit (PCAS) 2016Composed of Korean Prostate Cancer Experts

  • 1Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
  • 2Department of Urology, Konyang University College of Medicine, Daejeon, Korea
  • 3Department of Urology, Jeonbuk National University Medical School, Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Korea
  • 4Department of Urology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea
  • 5Department of Urology, Wonkwang University Hospital, Iksan, Korea
  • 6Department of Urology, Korea University College of Medicine, Seoul, Korea
  • 7Department of Urology, Ewha Womans University College of Medicine, Seoul, Korea
  • 8Department of Urology, Yonsei University College of Medicine, Seoul, Korea
  • 9Department of Urology, Seoul Metropolitan Government, Seoul National University Boramae Medical Center, Seoul, Korea
  • 10Department of Urology, Korea Cancer Centre Hospital, Seoul, Korea
  • 11Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Korea
  • 12Department of Urology, Seoul National University Hospital, Seoul National University School of Medicine, Seoul, Korea
  • 13Department of Urology, Chonnam National University Medical School, Gwangju, Korea
  • 14Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea


The Advanced Prostate Cancer Consensus Conference (APCCC) 2015 was based on topics withcontroversy in the field of advanced prostate cancer. To understand the Korean urologists perspective regardingthe issues, we have conducted a questionnaire named Prostate Cancer Summit (PCAS) 2016, with 9 importantsubtopics.
Materials and Methods
Total 9 subtopics have been decided and questions were developed regarding eachsubtopic. The questions were based on that of APCCC 2015 and translated into Korean for better understanding.Total 51 panelists have voted online on 85 different questions.
The survey concluded that testosterone should be measured as a diagnostic criterion for castrationresistance prostate cancer (CRPC) and that consensus was reached on issues such as the use of androgenreceptor pathway inhibitors in the treatment of predocetaxel and postdocetaxel in CRPC patients. In addition,76% of the participants agreed that imaging tests were needed before new treatment in CRPC patients, anda majority of participants agreed that periodic imaging tests are necessary regardless of symptoms during treatmentfor CRPC. However, some issues, such as the use of prostate-specific antigen-based triggers for remediationin CRPC patients, the endocrine manipulation in nonmetastatic CRPC patients, and the onset of treatment inasymptomatic metastatic CRPC patients, were not agreed.
The results from PCAS 2016 has addressed some of the issues with controversy. Although thevoting results are subjective, it will help guide treatment decisions in topics with less evidence.


Advenced prostate cancer; CRPC; PCAS2016; APCCC2015
Full Text Links
  • KJUO
export Copy
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error